

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 38/00, 38/04, 38/12, C07K 5/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/42119</b> <b>(43) International Publication Date:</b> 26 August 1999 (26.08.99)
<b>(21) International Application Number:</b> PCT/US99/03350 <b>(22) International Filing Date:</b> 17 February 1999 (17.02.99)	<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
<b>(30) Priority Data:</b> 09/025,319 18 February 1998 (18.02.98) US  <b>(71) Applicant (for all designated States except US):</b> HARBOR-UCLA RESEARCH AND EDUCATION INSTITUTE [US/US]; 1124 West Carson Street, Torrance, CA 90502 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> YEAMAN, Michael, R. [US/US]; Harbor-UCLA Medical Center, 1000 West Carson Street, Torrance, CA 90502 (US). SHEN, Alexander, J. [US/US]; Harbor-UCLA Medical Center, 1000 West Carson Street, Torrance, CA 90502 (US).  <b>(74) Agents:</b> PARKHURST, David, G. et al.; Fulwider Patton Lee & Utecht, 10th floor, 10877 Wilshire Boulevard, Los Angeles, CA 90024 (US).	<b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
<b>(54) Title:</b> ANTIMICROBIAL PEPTIDES AND DERIVED METAPEPTIDES		
<b>(57) Abstract</b>  Antimicrobial agents comprising peptides are disclosed.		

## (2) INFORMATION FOR SEQ ID NO: 24:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 12

(B) TYPE: amino acid

5 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: no

(v) FRAGMENT TYPE: internal fragment

(ix) FEATURE

10 (A) NAME/KEY: CS-MIP1 $\beta$ 

(C) IDENTIFICATION METHOD: By experiment

(D) OTHER INFORMATION: microbicidal activities

 $P_{MIC} = -396.49$ ; MW = 1741.80; number of charged amino acids: 4

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

15

Ser Trp Val Gln Glu Tyr Val Tyr Asp Leu Glu Leu

10

## (2) INFORMATION FOR SEQ ID NO: 25:

20 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 16

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

25 (iii) HYPOTHETICAL: no

(v) FRAGMENT TYPE: internal fragment

(ix) FEATURE

(A) NAME/KEY: CS-FBP $\alpha$ 

(C) IDENTIFICATION METHOD: By experiment

30

(D) OTHER INFORMATION: microbicidal activities,

$P_{MIC} = -78.53$ ; MW = 1806.90; number of charged amino acids: 5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

Ala Asp Ser Gly Glu Gly Asp Phe Leu Ala Glu Gly Gly Gly

5

10

Val Arg

(2) INFORMATION FOR SEQ ID NO: 26:

(i) SEQUENCE CHARACTERISTICS:

10

(A) LENGTH: 20

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: no

15

(v) FRAGMENT TYPE: internal fragment

(ix) FEATURE

(A) NAME/KEY: CS-FBP $\alpha$ -TET

(C) IDENTIFICATION METHOD: By experiment

(D) OTHER INFORMATION: microbicidal activities,

20

$P_{MIC} = -248.89$ ; MW = 2361.70; number of charged amino acids: 7

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

Ala Asp Ser Gly Glu Gly Asp Phe Leu Ala Glu Gly Gly Gly

10

25

Val Arg Lys Leu Ile Lys

(2) INFORMATION FOR SEQ ID NO: 27:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 13

30

(B) TYPE: amino acid